



# Personalized medicine in interstitial lung diseases

Paolo Spagnolo<sup>a</sup>, Justin M. Oldham<sup>b</sup>, Mark G. Jones<sup>c</sup>, and Joyce S. Lee<sup>d</sup>

## Purpose of review

A number of recent studies have explored the possibility to apply personalized medicine to interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), the most common and deadly of the idiopathic interstitial pneumonias. In our review, we summarize and discuss the most recent literature on personalized medicine in IPF as well as hypersensitivity pneumonitis and sarcoidosis, with emphasis on patient subgroups for which a personalized approach to disease prognostication and management may become a reality in the near future.

## Recent findings

Most of the studies that have explored the applicability of personalized medicine to ILDs have been conducted in patients with IPF. Such studies have suggested the existence of several distinct disease subgroups defined by similar genetic profiles, molecular pathways, exposures and individual lifestyles. Personalized medicine in hypersensitivity pneumonitis is in its infancy. The development and applicability of personalized medicine to sarcoidosis, on the other hand, remains problematic for several reasons, including the lack of a diagnostic gold standard, the highly variable and unpredictable disease course, particularly across patients of different ethnicities, the poor correlation between disease activity and disease severity and the lack of a validated management algorithm.

## Summary

A number of distinct patient subgroups have been identified in ILDs. Although available data need to be validated longitudinally, the possibility to study homogeneous groups of patients may allow prediction of disease behavior and response to treatment with dramatic clinical implications.

## Keywords

hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, interstitial lung disease, personalized medicine, sarcoidosis

## INTRODUCTION

Interstitial lung diseases (ILDs), also referred to as diffuse parenchymal lung diseases, are a large and heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis, often sharing similar clinical, physiologic and radiological features. A broadly used classification categorizes ILDs as idiopathic interstitial pneumonias (IIPs), of which idiopathic pulmonary fibrosis (IPF) is the most common and severe; diseases related to connective tissue disease (CTD-ILDs), drug intake and occupational and environmental exposures and sarcoidosis [1]. Despite a steadily growing interest and clinical research in ILDs, patient management remains suboptimal, mainly because of the limited knowledge of disease pathogenesis and the highly variable and unpredictable disease course [2].

Personalized medicine is a medical approach that emphasizes the customization of healthcare, with all decisions and practices being tailored to individual patients [3]. The first step in personalized

medicine is the identification of biological markers (e.g. biomarkers), which, broadly speaking, can be defined as measurable factors – most often proteins, found in blood, body fluid or tissue but which can be also physiological measures such as forced vital capacity (FVC) or imaging measures – that carry

<sup>a</sup>Department of Cardiac, Thoracic and Vascular Sciences, Section of Respiratory Diseases, University of Padova, Padova, Italy, <sup>b</sup>Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, The University of California at Davis, Sacramento, California, USA, <sup>c</sup>National Institute for Health Research Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, University of Southampton, Southampton, UK and <sup>d</sup>Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA

Correspondence to Professor Paolo Spagnolo, MD, PhD, Department of Cardiac, Thoracic and Vascular Sciences, Section of Respiratory Diseases, University of Padova, via Giustiniani 3, 35128 Padova, Italy. Tel: +39 049 8211272; fax: +39 049 8213110; e-mail: paolo.spagnolo@unipd.it

**Curr Opin Pulm Med** 2017, 23:000–000

DOI:10.1097/MCP.0000000000000370

## KEY POINTS

- A number of biological molecules with potential utility for the diagnosis, assessment of disease activity, prediction of disease behavior and response to treatment have recently been evaluated in ILDs.
- The possibility to apply personalized medicine to ILDs has been explored more convincingly to IPF, wherein distinct disease subsets – defined by different genetics, molecular pathways, exposures and patient lifestyles – have been described.
- A growing body of evidence suggests that patient genetic make-up may be important in treatment decision-making by defining subgroups of patients who share specific pathogenetic profiles and are therefore more likely to respond to a given therapy.
- At present, no biomarker is ready for routine use in clinical practice or trials of pharmacological interventions, but a number of biomarkers that are currently being validated in longitudinal studies may be available in the near future.

information about the health or disease state of the individual assayed [4]. Personalized healthcare has been successfully applied in a number of diseases, including cancers [5], although major scientific and logistical challenges still hinder its implementation in daily clinical practice [6]. Whether a personalized approach to diagnosis and care can be applied practically and in a cost-efficient manner to ILDs is a matter of vivid debate [7].

In the past few years, the role of biomarkers in ILDs has been increasingly appreciated, and clinical applicability of some such markers in the near future can be anticipated. In this review, we summarize recent data on promising candidate biomarkers in ILDs and discuss their potential to revolutionize our approach to disease classification, diagnosis and treatment.

## IDIOPATHIC PULMONARY FIBROSIS

IPF is the most common and deadly of the IIPs [8], with an estimated prevalence of 18–63 cases per 100 000 and 6–17 new cases per 100 000 yearly [9,10]. True epidemiologic data remain difficult to ascertain, however, as common case finding methodologies were recently shown to have a marginal positive predictive value for IPF [11<sup>■</sup>]. Similar difficulties lie with disease prognostication. IPF has a highly heterogeneous natural history, whereby most individuals experience steady pulmonary function decline, some demonstrate relative stability and others die from rapidly progressive disease [12,13].

Current clinical prediction models [14,15] identify those at an increased risk of mortality, but fail to predict disease progression, as measured by pulmonary function decline [16<sup>■</sup>,17<sup>■</sup>]. These realities make IPF a frustrating disease for patients and clinicians alike, and have led to substantial investigation aimed at identifying subgroups that display differential outcomes and treatment response. Such investigation forms the backbone of personalized medicine in IPF, which aims to optimize disease prognostication and management by incorporating environmental, phenotypic and biomarker data into risk stratification models and treatment algorithms. Below are examples of promising subgroups for which personalized medicine may soon become a reality.

## Gastroesophageal reflux/hiatal hernia subgroups

Gastroesophageal reflux (GER) is among the most commonly encountered comorbid conditions in patients with IPF and represents a potential cause of IPF via alveolar injury from aspirated stomach contents [18<sup>■</sup>]. Although estimates vary, GER has been described in up to 87% of individuals with IPF using 24-h esophageal potential of hydrogen monitoring [19]. Asymptomatic GER and nonacid GER are also common in IPF [19,20<sup>■</sup>], complicating the manner in which GER is diagnosed and prevalence determined. In addition to GER, a large minority of patients with IPF also suffer from a hiatal hernia, which may exacerbate GER and further contribute to microaspiration [21,22].

GER is typically treated with antacid therapy, including proton pump inhibitors and histamine-2 blockers. Data regarding the benefit of such therapy are conflicting and currently limited to retrospective analyses [23,24,25<sup>■</sup>]. Although initial studies suggested improved outcomes in those treated with antacid therapy [23,24], a recent posthoc analysis of pooled IPF clinical trial datasets failed to replicate these findings and demonstrated an increased incidence of pulmonary infections [25<sup>■</sup>]. Formal testing of antacid therapy is underway in a phase II clinical trial titled ‘Pilot Trial of Omeprazole in Idiopathic Pulmonary Fibrosis (PPIPF)’ (NC02085018). Although the results of this investigation will no doubt be informative, the concern remains that acid blockade fails to prevent the aspiration of stomach contents, irrespective of content acidity. As such, the mechanical correction of GER is also under investigation in a phase II clinical trial, titled ‘Treatment of IPF with Laparoscopic Anti-Reflux Surgery (WRAP-IPF)’ (NCT01982968). In addition to laying the foundation for larger, phase III trials, these investigations will begin to delineate whether such

interventions benefit IPF subgroups with comorbid GER and hiatal hernia.

### Airway microbiome subgroups

Microbes have long been implicated in the pathogenesis of IPF. Early studies suggested a potential role for several human herpes viruses, as these were found in higher proportions of individuals with IPF than control individuals [26–31]. Whether such viruses lead to the alveolar injury characteristic of IPF remains unclear, however. Recent investigations of the lower airway microbiome have shed light on bacterial pathogens as well. Molyneaux *et al.* [32] demonstrated a more than two-fold higher bacterial burden in the bronchoalveolar lavage fluid of patients with IPF compared with control individuals. Furthermore, increasing bacterial burden predicted both pulmonary function decline and death in this IPF cohort. In a similar investigation, Han *et al.* [33] showed that the presence of *Streptococcal* and *Staphylococcal* species predicted IPF progression and reduced progression-free survival. These findings, in addition to a recent randomized placebo-controlled trial showing that cotrimoxazole may improve survival in IPF [34], support an upcoming, phase III multicenter clinical trial titled ‘Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis’ (CleanUp)<sup>®</sup> (NCT02759120). This trial will not only determine whether antimicrobials represent an efficacious adjunct to antifibrotic therapy in IPF, but will also allow for the testing of such therapy in prespecified, microbiome-derived subgroups.

### Genetic subgroups

Although environmental risk factors have long been known in IPF, genetic risk factors have only recently begun to be delineated. Genome-wide association studies identified single nucleotide polymorphisms (SNPs) across multiple loci to be associated with IPF susceptibility [35,36]. Several SNPs are located on the short arm of chromosome 11, within *MUC5B* and *TOLLIP*, both of which play vital roles in airway host defense [32,37–39]. A recent investigation by Fingerlin *et al.* [40<sup>\*\*\*</sup>] identified an additional novel locus within human leukocyte antigen (HLA) complex, underscoring the potential role that impaired host defense plays in IPF pathogenesis. In addition to their association with IPF susceptibility, SNPs within *MUC5B* and *TOLLIP* have also been linked to differential survival, though the strength of association varies depending on the cohort under consideration [36,41–43]. A recent pharmacogenetic investigation [44<sup>\*\*\*</sup>] also showed that a common SNP within *TOLLIP*

may also modulate the response to *N*-acetylcysteine therapy, an antioxidant commonly used to treat IPF before a phase III clinical trial failed to demonstrate efficacy [45]. Although such outcome analyses are novel, they are reliant on SNPs linked to IPF susceptibility. Given the aforementioned heterogeneity in IPF natural history, a genome-wide investigation aimed at identifying SNPs specifically linked to IPF outcomes would greatly enhance our ability to incorporate genetics into risk stratification models. Such work would also synergize with current gene expression work aimed at predicting mortality [46], and allow for the testing of IPF-specific therapies in cohorts genetically predisposed to a poor outcome.

### HYPERSENSITIVITY PNEUMONITIS

Hypersensitivity pneumonitis is an ILD triggered by inhaled antigens, with multiple known causative agents. Recently Cramer *et al.* [47] studied the risk of hypersensitivity pneumonitis among pigeon breeders in a retrospective study and identified an adjusted hazard ratio of 14.36 (95% confidence interval 8.10–25.44) for hypersensitivity pneumonitis and other ILDs for pigeon breeders. Although still rare, this finding suggests that protective measures should be considered among pigeon breeders to minimize antigen exposure.

Diagnosis of hypersensitivity pneumonitis can be challenging, with wide variability in clinical, radiographic and pathologic findings and a possible initiating antigen identified in only around 50% of cases [48,49]. To aid diagnosis of hypersensitivity pneumonitis, Johannson *et al.* [50<sup>■</sup>] have proposed clinical prediction models (cross-validated C-statistic 75.2–78.0) incorporating only clinical and radiographic features including age, history of down feather and/or bird exposure and the presence of ground-glass opacity and mosaic perfusion on chest computed tomography. A group of patients with chronic hypersensitivity pneumonitis develop progressive fibrosis with associated morbidity and mortality. Long *et al.* [51<sup>■</sup>] have identified that baseline serum levels of YKL-40, a chitinase-like protein mainly secreted by macrophages, neutrophils and epithelial cells, were significantly higher in patients with chronic hypersensitivity pneumonitis than healthy controls, and patients who progressed or died had higher baseline YKL-40 levels than those who remained stable and survived. This finding requires external validation; however, it suggests that serum YKL-40 may have utility as a prognostic biomarker in hypersensitivity pneumonitis patients.

The standard of care for chronic hypersensitivity pneumonitis is antigen removal and corticosteroids; yet, the antigen may not be identified and patients

may continue to progress or have corticosteroid related side-effects. Alternative evidence-based therapeutic approaches are therefore required. Morisset *et al.* [52] performed a retrospective multicentre study of the cell cycle inhibitors mycophenolate mofetil (MMF) and azathioprine (AZA). Longitudinal trajectories in lung function were analyzed prior to, and after treatment initiation. Both treatments were generally well tolerated. No change in lung volumes (FVC) was identified; however, there was an improvement in gas transfer (diffusion capacity of the lung for carbon monoxide) of 4.2% ( $P < 0.001$ ) after 1 year of treatment. These retrospective data are supportive of the need for prospective randomized clinical trials to study the long-term efficacy of MMF and AZA in chronic hypersensitivity pneumonitis.

In patients with advanced, chronic hypersensitivity pneumonitis, lung transplantation may be considered; however, data on outcomes following transplantation have been limited. Kern *et al.* [53] performed a single centre retrospective analysis of all patients undergoing transplantation with a diagnosis of hypersensitivity pneumonitis. Thirty-one individuals with hypersensitivity pneumonitis had undergone transplant, with the diagnosis made only at explant in five cases. At 5 years, posttransplant survival was 67% (compared with 49% in a group of patients with IPF). In two patients, a recurrence of hypersensitivity pneumonitis in allograft was identified, demonstrating the need for vigilance for ongoing antigen exposure and disease recurrence following transplantation for hypersensitivity pneumonitis.

## SARCOIDOSIS

Sarcoidosis is a systemic granulomatous disorder with a wide-ranging pattern of presentation and severity [54]. Although the cause of the disease remains unknown, a large body of evidence indicates that susceptibility to sarcoidosis is genetically determined [55]. The disease, however, is not caused by defects in a single major gene or chemical pathway; instead, it results from a complex interaction between environmental/infectious agents and multiple genes, some with a major disease effect, but many with a relatively minor effect [56]. Genetics is also believed to contribute to the highly variable clinical manifestations and prognosis of sarcoidosis [56].

Consistent with the concept that sarcoidosis granulomatous inflammation results from an abnormal immune response to persistent antigenic stimuli, several HLA alleles have been associated with the disease [55]. However, there is a considerable variability in the alleles that are associated with increased disease risk or 'protection' across different ethnicities,

which makes the personalization of genetic susceptibility/protection very challenging at this moment. There is one situation, however, in which a genetic association is robust across different populations, and is practical and clinically relevant. This is the HLA-DRB1\*0301 (DR3) association with Löfgren's syndrome, an acute and almost invariably benign form of sarcoidosis that manifests with fever, bilateral hilar lymphadenopathy and erythema nodosum with or without periarticular inflammation of the ankles [57]. Notably, approximately 50% of individuals who present with Löfgren's syndrome but do not carry the DR3 allele experience persistent disease and a less favorable outcome [57].

Recent studies have highlighted the potential of immune mediators and immunogenetics in determining disease development and behavior, and guiding treatment in sarcoidosis. Levin *et al.* [58] genotyped a large population of African American patients ( $n = 1277$ ) and matched controls ( $n = 1467$ ), and found that, consistent with previous findings among individuals of European descent [57], carriage of the HLA-DRB1\*0301 allele is associated with a resolving disease course. Owing to the high likelihood of experiencing a self-limiting disease course, treatment may be contraindicated in sarcoidosis patients carrying the HLA-DRB1\*0301 allele. Fischer *et al.* [59] recently performed the largest sarcoidosis case-control study to date. In the screening step, they genotyped a European cohort of 1726 patients and 5482 controls using the Illumina ImmunoChip SNP array, whereas multiple European cohorts and one African American cohort were used for replication and subgroup analysis. They identified novel disease susceptibility loci with genome-wide significance at 12q24.12 (ATXN2/SH2B3), 5q33.3 (near IL12B), 4q24 (MANBA/NFKB1), 2q33.2 (FAM117B) and 1p31.3 (IL23R) along with three independent signals in the HLA region. Notably, this study suggests a significant genetic overlap between sarcoidosis and other immune-mediated inflammatory disorders, thus providing hypotheses for novel therapeutic targets.

As with other ILDs, the main goal of personalized medicine in the management of sarcoidosis is the identification of biomarkers to predict disease behavior and response to treatment. Indeed, it is well known that a person's genes influence his/her responses to drugs, both in terms of therapeutic effect and adverse effect. Testing leukemia patients for their thiopurine S-methyltransferase (*TPMT*) status is one of the most common examples of treatment being tailored to match patients' genetics [60]. In sarcoidosis, *TPMT* genotype may potentially affect response to thiopurines such as azathioprine and methotrexate, two commonly used second-line

steroid-sparing agents [61,62], although this has never been formally addressed in adequately powered clinical studies. Patients who experience disease progression despite (or intolerable side-effects from) conventional therapy are usually treated with antitumor necrosis factor (TNF) monoclonal antibodies, especially in organ-threatening or life-threatening disease [63]. Wijnen *et al.* [64] evaluated the contribution of TNF- $\alpha$  G-308A genotype to response to anti-TNF- $\alpha$  treatment in 111 patients with refractory sarcoidosis. They observed that individuals homozygous for the G allele were more likely to respond to anti-TNF treatment (either infliximab or adalimumab) compared with carriers of the AA or GA genotype. Personalized prescribing has the potential to revolutionize the landscape of sarcoidosis treatment; at present, however, there is very limited evidence for it to be applied to clinical practice [65].

The development and applicability of biomarker tools to sarcoidosis remains problematic for several reasons, including the lack of a diagnostic gold standard; the highly variable mode of presentation, manifestations and outcome; the poor correlation between disease activity and disease severity; and the lack of a validated management algorithm [66]. As such, the added value of biomarkers over the standard clinical assessment in patients with sarcoidosis remains to be established.

## CONCLUSION

Over the past few years, genetic and molecular approaches have improved dramatically our knowledge of the genetic heterogeneity of ILDs, particularly IPF. These studies have suggested the possibility to stratify patients on a pathway-specific basis, thus allowing for the testing of therapies in more homogeneous cohorts. Disease prognostication and management will also benefit from incorporation of environmental and phenotypic data into risk stratification models and treatment algorithms. The importance of personalized medicine in ILDs remains to be established and much work is needed to prospectively validate available data. If successful, however, this approach has the potential to transform the diagnosis, classification and management of these challenging diseases.

## Acknowledgements

None.

## Financial support and sponsorship

*This work was supported by the Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy (Grant BIRD163522) (P.S.).*

*P.S. has served as a consultant for InterMune, Roche/Genentech and Santhera Pharmaceuticals, has served on scientific advisory boards for Boehringer-Ingelheim and has received speaking honoraria from InterMune, Roche/Genentech, Boehringer Ingelheim, Zambon and Novartis.*

*J.M.O. has received grants from the American Lung Association, American Thoracic Society and Boehringer-Ingelheim outside the submitted work and has received speaking honoraria from Genentech and Boehringer-Ingelheim.*

## Conflicts of interest

*The remaining authors have no conflicts of interest.*

## REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2002; 165:277–304; Erratum in: *Am J Respir Crit Care Med* 2002; 166:426.
2. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. *Lancet Respir Med* 2014; 2:416–428.
3. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015; 372:793–795.
4. Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. *Curr Opin Pulm Med* 2015; 21:470–478.
5. Swanton C, Soria JC, Bardelli A, *et al.* Consensus on precision medicine for metastatic cancers: a report from the MAP conference. *Ann Oncol* 2016; 27:1443–1448.
6. Arnedos M, Vicier C, Loi S, *et al.* Precision medicine for metastatic breast cancer: limitations and solutions. *Nat Rev Clin Oncol* 2015; 12:693–704.
7. Brownell R, Kaminski N, Woodruff PG, *et al.* Precision medicine: the new frontier in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 193:1213–1218.
8. Raghu G, Collard HR, Egan JJ, *et al.* An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis – evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011; 183:788–824.
9. Fernandez Perez ER, Daniels CE, Schroeder DR, *et al.* Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. *Chest* 2010; 137:129–137.
10. Raghu G, Chen SY, Hou Q, *et al.* Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. *Eur Respir J* 2016; 48:179–186.
11. Esposito DB, Lanes S, Donneyong M, *et al.* Idiopathic pulmonary fibrosis in United States automated claims. Incidence, prevalence, and algorithm validation. *Am J Respir Crit Care Med* 2015; 192:1200–1207.

This study shows that estimates of IPF incidence and prevalence from electronic databases may be inaccurate, and that sensitive algorithms without correction for false-positive errors overestimate incidence and prevalence of IPF.

12. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011; 183:431–440.
13. Selman M, Carrillo G, Estrada A, *et al.* Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. *Plos One* 2007; 2:e482.
14. Ley B, Ryerson CJ, Vittinghoff E, *et al.* A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med* 2012; 156:684–691.
15. Wells AU, Desai SR, Rubens MB, *et al.* Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. *Am J Respir Crit Care Med* 2003; 167:962–969.
16. Ley B, Bradford WZ, Vittinghoff E, *et al.* Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 194:711–718.

This study shows that models for time to respiratory hospitalization or death, or death alone display acceptable discriminative performance, whereas clinical prediction models poorly predict functional disease progression in IPF.

17. Salisbury ML, Xia M, Zhou Y, *et al*. Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline. *Chest* 2016; 149:491–498.

This study suggests that baseline gender, age, physiology stage predicts death or lung transplantation but not the rate of future pulmonary function decline.

18. Raghu G, Rochwerf B, Zhang Y, *et al*. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med* 2015; 192:e3–e19.

A recent guideline document that provides evidence-based recommendations on pharmacological interventions for IPF.

19. Raghu G, Freudenberger TD, Yang S, *et al*. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. *Eur Respir J* 2006; 27:136–142.

20. Gavini S, Finn RT, Lo WK, *et al*. Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to nonfibrotic disease among prelung transplant patients. *Neurogastroenterol Motil* 2015; 27:1326–1332.

This retrospective study confirms that abnormal gastro-oesophageal reflux is highly prevalent in patients with IPF and suggests a role for pathological gastro-oesophageal reflux in the development of the disease.

21. Noth I, Zangan SM, Soares RV, *et al*. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. *Eur Respir J* 2012; 39:344–351.

22. Tossier C, Dupin C, Plantier L, *et al*. Hiatal hernia on thoracic computed tomography in pulmonary fibrosis. *Eur Respir J* 2016; 48:833–842.

23. Lee JS, Collard HR, Anstrom KJ, *et al*. Antiacid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. *Lancet Respir Med* 2013; 1:369–376.

24. Lee JS, Ryu JH, Elicker BM, *et al*. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011; 184:1390–1394.

25. Kreuter M, Wuyts W, Renzoni E, *et al*. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. *Lancet Respir Med* 2016; 4:381–389.

This posthoc analysis of the placebo groups of three trials of pirfenidone suggests that antacid therapy may not be beneficial in patients with IPF and may actually be associated with an increased risk of infection in individuals with advanced disease.

26. Vergnon JM, Vincent M, de The G, *et al*. Cryptogenic fibrosing alveolitis and Epstein–Barr virus: an association? *Lancet* 1984; 2:768–771.

27. Manika K, Alexiou-Daniel S, Papakosta D, *et al*. Epstein–Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2007; 24:134–140.

28. Stewart JP, Egan JJ, Ross AJ, *et al*. The detection of Epstein–Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1999; 159:1336–1341.

29. Kelly BG, Lok SS, Hasleton PS, *et al*. A rearranged form of Epstein–Barr virus DNA is associated with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2002; 166:510–513.

30. Tang YW, Johnson JE, Browning PJ, *et al*. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. *J Clin Microbiol* 2003; 41:2633–2640.

31. Lasithiotaki I, Antoniou KM, Vlahava VM, *et al*. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. *Plos One* 2011; 6:e27800.

32. Molyneaux PL, Cox MJ, Willis-Owen SA, *et al*. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2014; 190:906–913.

33. Han MK, Zhou Y, Murray S, *et al*. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. *Lancet Respir Med* 2014; 2:548–556.

34. Shulgina L, Cahn AP, Chilvers ER, *et al*. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. *Thorax* 2013; 68:155–162.

35. Fingerlin TE, Murphy E, Zhang W, *et al*. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat Genet* 2013; 45:613–620.

36. Noth I, Zhang Y, Ma S-F, *et al*. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. *Lancet Respir Med* 2013; 1:309–317.

37. Roy MG, Livraghi-Butrico A, Fletcher AA, *et al*. Muc5b is required for airway defence. *Nature* 2014; 505:412–416.

38. Shah JA, Vary JC, Chau TT, *et al*. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. *J Immunol* 2012; 189:1737–1746.

39. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. *J Biol Chem* 2002; 277:7059–7065.

40. Fingerlin TE, Zhang W, Yang IV, *et al*. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. *BMC Genet* 2016; 17:74.

This study reports two novel associations between HLA alleles and familial IIPs, suggesting a potential role for autoimmunity in the pathogenesis of the disease.

41. Peljto AL, Zhang Y, Fingerlin TE, *et al*. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA* 2013; 309:2232–2239.

42. van der Vis JJ, Snetelaar R, Kazemier KM, *et al*. Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. *Respirology* 2016; 21:712–717.

43. Jiang H, Hu Y, Shang L, *et al*. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. *Int J Clin Exp Pathol* 2015; 8:14953–14958.

44. Oldham JM, Ma SF, Martinez FJ, *et al*. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2015; 192:1475–1482.

This study, the first pharmacogenomic study in IPF, suggests that N-acetylcysteine may be beneficial for a subset of patients, those carrying the TOLLIP rs3750920 TT genotype.

45. Martinez FJ, de Andrade JA, Anstrom KJ, *et al*. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370:2093–2101.

46. Herazo-Maya JD, Noth I, Duncan SR, *et al*. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. *Sci Transl Med* 2013; 5:205ra136.

47. Cramer C, Bendstrup E, Stokholm ZA, *et al*. Risk of hypersensitivity pneumonitis and interstitial lung diseases among pigeon breeders. *Eur Respir J* 2016; 48:818–825.

48. Spagnolo P, Rossi G, Cavazza A, *et al*. Hypersensitivity pneumonitis: a comprehensive review. *J Investig Allergol Clin Immunol* 2015; 25:237–250.

49. Elicker BM, Jones K, Henry TS, Collard HR. Multidisciplinary approach to hypersensitivity pneumonitis. *J Thorac Imaging* 2016; 31:92–103.

50. Johannson KA, Elicker BM, Vittinghoff E, *et al*. A diagnostic model for chronic hypersensitivity pneumonitis. *Thorax* 2016; 71:951–954.

The authors of this study developed a model that allows with high specificity for a diagnosis of chronic hypersensitivity pneumonitis using clinical and radiological variables alone.

51. Long X, He X, Ohshimo S, *et al*. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. *Eur Respir J* 2016; pii: ERJ-01924-2015. doi: 10.1183/13993003.01924-2015. [Epub ahead of print]

This study suggests that serum YKL-40 may be a useful prognostic biomarker in patients with hypersensitivity pneumonitis. In fact, different cutoff levels at baseline predict disease progression and mortality.

52. Morisset J, Johannson KA, Vittinghoff E, *et al*. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. *Chest* 2016; pii: S0012-3692(16)62296-1. doi: 10.1016/j.chest.2016.10.029. [Epub ahead of print]

53. Kern RM, Singer JP, Koth L, *et al*. Lung transplantation for hypersensitivity pneumonitis. *Chest* 2015; 147:1558–1565.

54. Valeyre D, Prasse A, Nunes H, *et al*. Sarcoidosis. *Lancet* 2014; 383:1155–1167.

55. Fischer A, Grunewald J, Spagnolo P, *et al*. Genetics of sarcoidosis. *Semin Respir Crit Care Med* 2014; 35:296–306.

56. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. *J Med Genet* 2013; 50:290–297.

57. Grunewald J, Eklund A. Löfgren's syndrome: human leukocyte antigen strongly influences the disease course. *Am J Respir Crit Care Med* 2009; 179:307–312.

58. Levin AM, Adrianto I, Datta I, *et al*. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. *Am J Respir Cell Mol Biol* 2015; 53:206–216.

59. Fischer A, Ellinghaus D, Nutsua M, *et al*. Identification of immune-relevant factors conferring sarcoidosis genetic risk. *Am J Respir Crit Care Med* 2015; 192:727–736.

This study indicates a prominent role of the interleukin-23/T helper 17 signaling pathway in the pathogenesis of sarcoidosis, thus revealing a substantial genetic overlap between sarcoidosis and several immune-mediated inflammatory disorders.

60. Drew L. Pharmacogenetics: the right drug for you. *Nature* 2016; 537: S60–S62.

61. Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. *Curr Opin Pulm Med* 2007; 13:458–463.

62. Vorseelaars AD, Cremers JP, Grutters JC, Drent M. Cytotoxic agents in sarcoidosis: which one should we choose? *Curr Opin Pulm Med* 2014; 20:479–487.

63. Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. *Lancet Respir Med* 2015; 3:813–822.

64. Wijnen PA, Cremers JP, Nelemans PJ, *et al*. Association of the TNF- $\alpha$  G-308A polymorphism with TNF-inhibitor response in sarcoidosis. *Eur Respir J* 2014; 43:1730–1739.

65. Petrek M. Personalized medicine in sarcoidosis: predict responders and nonresponders. *Curr Opin Pulm Med* 2015; 21:532–537.

66. Chopra A, Kalkanis A, Judson MA. Biomarkers in sarcoidosis. *Expert Rev Clin Immunol* 2016; 12:1191–1208.